Celldex

Nasdaq: CLDX · SEC EDGAR filings

Results on file1
Average 24h move−11.59%across 1 result with a complete 24h price
1 resultCelldex
Met endpoint

Barzolvolimab

Phase 3 n=963 Chronic Spontaneous Urticaria

Celldex CLDX

24h stock move −11.59%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.